Emanuelle Araujo Lima Bellaguarda

Personal profile

Research Interests

Inflammatory bowel disease (Crohn's disease and ulcerative colitis), therapeutic drug monitoring, clinical trials

Training Experience

2011	Residency, Boston University Medical Center
2014	Fellowship, University of Chicago
2015	Fellowship, Northwestern University, Feinberg School of Medicine

Education/Academic qualification

MD, Federal University of Ceara, Brazil

… → 2006

Research interests

Inflammatory Bowel Disease

Fingerprint Dive into the research topics where Emanuelle Araujo Lima Bellaguarda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Crohn Disease Medicine & Life Sciences

Inflammatory Bowel Diseases Medicine & Life Sciences

JC Virus Medicine & Life Sciences

Stomatitis Medicine & Life Sciences

alanylglutamine Medicine & Life Sciences

Methotrexate Medicine & Life Sciences

Fluorouracil Medicine & Life Sciences

Cricetinae Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2017 2022

1 Finished
9 Active

Prot#M16-006: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease (M16-006)

Bellaguarda, E. A. L.

AbbVie Inc.

7/23/19 → 7/22/22

Project: Research project

Semen quality in males with inflammatory bowel disease and inflammatory joint disease: Influence of ustekinumab and tofacitinib treatment

Bellaguarda, E. A. L.

Northwestern Memorial Hospital, Digestive Health Foundation

7/1/19 → 6/30/20

Project: Research project

Protocol M15-991: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who failed Prior Biologic Treatment (Abbvie M15-

Bellaguarda, E. A. L.

AbbVie Inc.

6/14/19 → 6/14/22

Project: Research project

Protocol VDZ-5034: Entyvio Outcomes in Real World Bio-Naïve Ulcerative Colitis and Crohn’s Disease Patients (EVOLVE)- USA Study Protocol

Bellaguarda, E. A. L.

PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.

10/10/18 → 10/10/21

Project: Research project

Vedolizumab-4014: A Phase 4, Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders With Moderately to Severely Active Ulcerative Colitis

Bellaguarda, E. A. L.

Quintiles, Inc., Takeda Development Center Americas, Inc.

6/19/18 → 6/19/21

Project: Research project

Research Output 2007 2019

177 Citations
7 Article
2 Review article
1 Letter

1 Citation (Scopus)

Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis

Limketkai, B. N., Shah, S. C., Hirano, I., Bellaguarda, E. A. L. & Colombel, J. F., Jan 1 2019, In : Gut.

Research output: Contribution to journal › Article

Eosinophilic Esophagitis

Epidemiology

Population

Crohn Disease

Incidence

20 Citations (Scopus)

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E. A. L., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., Singh, S., Pekow, J. & Rubin, D. T., Mar 1 2018, In : Alimentary Pharmacology and Therapeutics. 47, 6, p. 753-762 10 p.

Research output: Contribution to journal › Article

Sclerosing Cholangitis

Inflammatory Bowel Diseases

Biochemistry

Liver

Ulcerative Colitis

4 Citations (Scopus)